Long-term olanzapine treatment and P300 parameters in Schizophrenia

Neuropsychobiology

Volumn 50, Issue 2, 2004, Pages 182-188

  Molina, Vicente ^a   Muñoz, Francisco ^b   Martín Loeches, Manuel ^b   Casado, Pilar ^b   Hinojosa, José A ^b   Iglesias, Alfonso ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Olanzapine; P300; Schizophrenia

Indexed keywords

OLANZAPINE;

ADULT; AMPLITUDE MODULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRODE; FEMALE; HUMAN; LATENT PERIOD; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; AUDITORY PERCEPTION; BENZODIAZEPINES; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; FEMALE; HALOPERIDOL; HUMANS; LONGITUDINAL STUDIES; MALE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 4043069364     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079112     Document Type: Article

References (17)

1. Ford JM, White PM, Csernansky JG, Faustman WO, Roth WT, Pfefferbaum A: ERPs in schizophrenia: Effects of antipsychotic medication. Biol Psychiatry 1994;36:153-170.
2. Iwanami A, Okajima Y, Isono H, Shinoda J, Kasai K, Hata A, Fukuda M, Nakagome K, Kamijima K: Effects of risperidone on event-related potentials in schizophrenic patients. Pharmacopsychiatry 2001;34:73-79.
3. Gallinat J, Riedel M, Juckel G, Sokullu S, Frodl T, Moukhtieva R, Mavrogiorgou P, Nissle S, Muller N, Danker-Hopfe H, Hegerl U: P300 and symptom improvement in schizophrenia. Psychopharmacology (Berl) 2001;158:55-65.
4. Hubl D, Kleinlogel H, Frolich L, Weinandi T, Maurer K, Holstein W, Czekalla J, Dierks T: Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine. Psychopharmacology (Berl) 2001;158:281-288.
5. Gonul AS, Suer C, Coburn K, Ozesmi C, Oguz A, Yilmaz A: Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:173-177.
6. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia. Arch Gen Psychiatry 2000;57:249-258.
7. Donchin E, Karis D, Bashore TR, Coles MGH, Gratton G: Cognitive psychophysiology and human information processing; in Coles MGH, Donchin E, Porges SW (eds): Psychophysiology: Systems Processes, and Applications. New York, Guilford Press, 1988, pp 244-267.
8. Ford JM: Schizophrenia: The broken P300 and beyond. Psychophysiology 1999;36:667-682.
9. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL: Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000;157:767-771.
10. Gur RE, Kohler C, Ragland JD, Siegel SJ, Bilker WB, Loughead J, Phend N, Gur RC: Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. Neuropsychopharmacology 2003;28:2029-2036.
11. Hollingshead A, Frederick R: Social stratification and psychiatric disorders. Am Soc Rev 1953;18:163-189.
12. Semlitsch H, Anderer P, Schuster P, Presslich O: A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 1986;23:695-703.
13. Schall U, Catts SV, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, Ward PB: The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: Neuropsychology and event-related potential measures. Int J Neuropsychopharmacol 1998;1:19-29.
14. Mathalon DH, Ford JM, Pfefferbaum A: Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study. Biol Psychiatry 2000;47:434-449.
15. Turetsky B, Colbath EA, Gur RE: P300 sub-component abnormalities in schizophrenia. II. Longitudinal stability and relationship to symptom change. Biol Psychiatry 1998;43:31-39.
16. Martin-Loeches M, Molina V, Munoz F, Hinojosa JA, Reig S, Desco M, Benito C, Sanz J, Gabiri A, Sarramea F, Santos A, Palomo T: P300 amplitude as a possible correlate of frontal degeneration in schizophrenia. Schizophr Res 2001;49:121-128.
17. Kumari V, Soni W, Sharma T: Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 1999;156:1046-1051.